By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BGI today announced that it has signed a statement of intent with drug giant Merck to explore areas of mutual interest with the goal of "creating value" from the high volume of information resulting from next-generation sequencing technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.